Trial Profile

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IO 112 (Primary) ; Montanide ISA-51
Indications Advanced breast cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; First in man

Most Recent Events

19 Feb 2023 Status changed from recruiting to completed.
11 Feb 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
11 Feb 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com